All In Biotech

Drug Trial Radar · NCT07562087

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 722 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

722

Actual

Start

Mar 9, 2026

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Tarsus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.

Conditions

  • Lyme Disease

Interventions

  • TP-05 (lotilaner) Low DoseDrug

    TP05 administered orally at the protocol-defined preventative dose.

  • TP-05 (lotilaner) High DoseDrug

    TP05 administered orally at the protocol-defined preventative dose.

  • PlaceboDrug

    Matching placebo administered orally according to the same dosing schedule as TP05.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence of Treatment Emergent Adverse Events From BaselineTime frame: From day 1 through the end of study follow-up, an average of 15 months.
  2. Clinically Significant Changes From Baseline Chemistry Laboratory TestsTime frame: From day 1 through the end of study follow up, an average of 15 months.
  3. Clinically Significant Changes From Baseline Hematology Laboratory TestsTime frame: From day 1 through the end of study follow up, an average of 15 months.
  4. Clinically Significant Changes From Baseline Vital SignsTime frame: From day 1 through the end of study follow up, an average of 15 months.
  5. Clinically Significant Changes From Baseline Electrocardiograms (ECGs)Time frame: From day 1 through the end of study follow up, an average of 15 months.
  6. Clinically Significant Changes From Baseline Electrocardiograms (ECGs) MeasuresTime frame: From day 1 through the end of study follow up, an average of 15 months.
  7. Clinically Significant Changes From Baseline QTC IntervalTime frame: From day 1 through the end of study follow up, an average of 15 months.
  8. Clinically Significant Changes From Baseline QRS IntervalTime frame: From day 1 through the end of study follow up, an average of 15 months.

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site

    Pikesville, Maryland

  • Study Site

    Brookline, Massachusetts

  • Study Site

    Fall River, Massachusetts

  • Study Site

    Minneapolis, Minnesota

  • Study Site

    Marlboro, New Jersey

  • Study Site

    Albany, New York

  • Study Site

    Binghamton, New York

  • Study Site

    Buffalo, New York

  • Study Site

    East Syracuse, New York

  • Study Site

    Middletown, New York

  • Study Site

    New York, New York

  • Study Site

    Rochester, New York

  • Study Site

    Erie, Pennsylvania

  • Study Site

    Hatboro, Pennsylvania

  • Study Site

    Philadelphia, Pennsylvania

  • Study Site

    Pittsburgh, Pennsylvania

  • Study Site

    Pottstown, Pennsylvania

  • Study Site

    West Chester, Pennsylvania

  • Study Site

    Warwick, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.